Human Anti-D (rh) immunoglobulin
Phase 3Small molecule
Human Anti-D (rh) immunoglobulin is one of 11 small molecule programs targeting Pregnant Women. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Pregnant Women
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Tirosint
IInstitut Jerome Lejeune
Approved
Tdap Vaccine
SanofiPhase 3
GBS-NN/NN2
MMinervax ApS
Phase 3
Human Anti-D (rh) immunoglobulin
BBiopharma Plasma LLC
Phase 3
Hecolin ).
IInternational Vaccine Institute
Phase 2
Nicotinamide
MMetro International Biotech, LLC
Preclinical
IV Acetaminophen
AAFT Pharmaceuticals, Ltd.
Preclinical
Choline Bitartrate
UUniversity of Minnesota
Preclinical
Antiemetic Drug
UUniversity of West Attica
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBiopharma Plasma LLC